| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000033825 |
| Receipt No. | R000038581 |
| Official scientific title of the study | Single-blind, randomized controlled trial to assess the effect of blue-light alleviation on visual fatigue in healthy volunteers |
| Date of disclosure of the study information | 2018/08/20 |
| Last modified on | 2019/03/04 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Single-blind, randomized controlled trial to assess the effect of blue-light alleviation on visual fatigue in healthy volunteers | |
| Title of the study (Brief title) | Single-blind, randomized controlled trial to assess the effect of blue-light alleviation on visual fatigue in healthy volunteers | |
| Region |
|
|
| Condition | |||
| Condition | healthy volunteers | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To assess the effect of blue-light alleviation during visual load test on visual fatigue, physical stress, and discomfort, compared with general white light radiated from commercial desk lamp. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | change on critical flicker frequency (CFF) from before to after the visual load test |
| Key secondary outcomes | 1. change on ocular accommodation response from before to after the visual load test
2. change on accommodative microfluctuations from before to after the visual load test 3. change on visual acuity from before to after the visual load test 4. change on manifest refraction from before to after the visual load test |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -participants are blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Group A: blue-light alleviated desk lamp group | |
| Interventions/Control_2 | Group B: existing desk lamp group | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Subjects who meet all of the following criteria are included in this study.
1. subjects whose corrected visual acuity is 0.7 or higher 2. subjects who is aged from 16 to 22 at obtaining consent 3. male and female 4. Written consent form to participate in the study signed by subjects themselves after full explanation of this study and its ethical considerations. Minor subjects need additional written consent form signed by legal representative 5. subjects who can have the ophthalmological examinations at the day of the visual load tests according to the indication by the attending physicians |
|||
| Key exclusion criteria | Subjects who fall into any of the following criteria are excluded from participating in the study.
1. subjects who uses glasses 2. subjects who have any anamneses or complications which could affect the results of the study, such as dry eye, ophthalmological surgery, eye inflammation including allergic reaction, ocular infection, glaucoma, keratoconus, and diabetes mellitus 3. subjects who use any eye drops, oral medicines or dietary supplements whose objective are to alleviate visual fatigue or symptoms of eye diseases 4. subjects who were considered inappropriate to participate in this study by physicians |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Hidenaga Kobashi |
| Organization | Minamiaoyama Eye Clinic |
| Division name | Department of Ophthalmology |
| Address | 3-3-11 Kitaaoyama, Minato, Tokyo, Japan |
| TEL | 03-5772-1451 |
| himon@hotmail.co.jp | |
| Public contact | |
| Name of contact person | Hiroki Takayama |
| Organization | Soiken Inc. |
| Division name | Clinical Study Support Division |
| Address | NBF Ogawamachi Building 4F, 1-3-1 Ogawamachi, Kanda, Chiyoda-ku, Tokyo |
| TEL | 03-3295-1350 |
| Homepage URL | |
| takayama@soiken.com | |
| Sponsor | |
| Institute | Minamiaoyama Eye Clinic |
| Institute | |
| Department | |
| Funding Source | |
| Organization | BALMUDA Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038581 |